Amos, Christopher I.
Bale, Sherri J.
Arold, Stefan T.
KAUST DepartmentBiological and Environmental Sciences and Engineering (BESE) Division
Computational Bioscience Research Center (CBRC)
Permanent link to this recordhttp://hdl.handle.net/10754/325328
MetadataShow full item record
AbstractBackground: Peutz-Jeghers syndrome (PJS) is characterized by intestinal polyposis, mucocutaneous pigmentation and an increased cancer risk, usually caused by mutations of the STK11 gene. This study collected epidemiological, clinical and genetic data from all Uruguayan PJS patients. Methods: Clinical data were obtained from public and private medical centers and updated annually. Sequencing of the STK11 gene in one member of each family was performed. Results and discussion: 25 cases in 11 unrelated families were registered (15 males, 10 females). The average age of diagnosis and death was 18 and 41 years respectively. All patients had characteristic PJS pigmentation and gastrointestinal polyps. 72% required urgent surgery due to intestinal obstruction. 3 families had multiple cases of seizure disorder, representing 20% of cases. 28% developed cancer and two patients had more than one cancer. An STK11 mutation was found in 8 of the 9 families analyzed. A unique M136K missense mutation was noted in one family. Comparing annual live births and PJS birth records from 1970 to 2009 yielded an incidence of 1 in 155,000. Conclusion: The Uruguayan Registry for Peutz-Jeghers patients showed a high chance of emergent surgery, epilepsy, cancer and shortened life expectancy. The M136K missense mutation is a newly reported STK 11 mutation. © 2013 Tchekmedyian et al.
CitationTchekmedyian A, Amos CI, Bale SJ, Zhu D, Arold S, et al. (2013) Findings from the Peutz-Jeghers Syndrome Registry of Uruguay. PLoS ONE 8: e79639. doi:10.1371/journal.pone.0079639.
PublisherPublic Library of Science (PLoS)
PubMed Central IDPMC3834183
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
- Germline mutations of the STK11 gene in Korean Peutz-Jeghers syndrome patients.
- Authors: Yoon KA, Ku JL, Choi HS, Heo SC, Jeong SY, Park YJ, Kim NK, Kim JC, Jung PM, Park JG
- Issue date: 2000 Apr
- Novel mutations in the LKB1/STK11 gene in Dutch Peutz-Jeghers families.
- Authors: Westerman AM, Entius MM, Boor PP, Koole R, de Baar E, Offerhaus GJ, Lubinski J, Lindhout D, Halley DJ, de Rooij FW, Wilson JH
- Issue date: 1999
- Cancer risk associated with STK11/LKB1 germline mutations in Peutz-Jeghers syndrome patients: results of an Italian multicenter study.
- Authors: Resta N, Pierannunzio D, Lenato GM, Stella A, Capocaccia R, Bagnulo R, Lastella P, Susca FC, Bozzao C, Loconte DC, Sabbà C, Urso E, Sala P, Fornasarig M, Grammatico P, Piepoli A, Host C, Turchetti D, Viel A, Memo L, Giunti L, Stigliano V, Varesco L, Bertario L, Genuardi M, Lucci Cordisco E, Tibiletti MG, Di Gregorio C, Andriulli A, Ponz de Leon M, AIFEG.
- Issue date: 2013 Jul
- A novel mutation in STK11 gene is associated with Peutz-Jeghers Syndrome in Indian patients.
- Authors: Thakur N, Reddy DN, Rao GV, Mohankrishna P, Singh L, Chandak GR
- Issue date: 2006 Sep 30
- Mutations in STK11 gene in Czech Peutz-Jeghers patients.
- Authors: Vasovcák P, Puchmajerová A, Roubalík J, Krepelová A
- Issue date: 2009 Jul 19
Showing items related by title, author, creator and subject.
Cancer megafunds with <i>in silico</i> and <i>in vitro</i> validation: Accelerating cancer drug discovery <i>via</i> financial engineering without financial crisisYang, Xianjin; Debonneuil, Edouard; Zhavoronkov, Alex; Mishra, Bud (Oncotarget, Impact Journals, LLC, 2016-06-03) [Article]Advances in financial engineering are radically reshaping the biomedical marketplace. For instance, new methods of pooling diversified drug development programs by placing them in a special purpose vehicle (SPV) have been proposed to create a securitized cancer megafund allowing for debt and equity participation. In this study, we perform theoretical and numerical simulations that highlight the role of empirical validation of the projects comprising a cancer megafund. We quantify the degree to which the deliberately designed structure of derivatives and investments is key to its liquidity. Research megafunds with comprehensive in silico and laboratory validation protocols and ability to issue both debt, and equity as well as hybrid financial products may enable conservative investors including pension funds and sovereign government funds to profit from unique securitization opportunities. Thus, while hedging investor's longevity risk, such well-validated megafunds will contribute to health, well being and longevity of the global population.
Variants Prioritization in Cancer: Understanding and Predicting Cancer Driver Genes and MutationsAlthubaiti, Sara (2018-11-08) [Thesis]
Advisor: Hoehndorf, Robert
Committee members: Moshkov, Mikhail; Arold, Stefan T.Millions of somatic mutations in human cancers have been identified by sequenc- ing. Identifying and distinguishing cancer driver genes amongst the millions of candi- date mutations remains a major challenge. Accurate identification of driver genes and mutations is essential for the progress of cancer research and personalizing treatment based on accurate stratification of patients. Because of inter-tumor genetic hetero- geneity, numerous driver mutations within a gene can be found at low frequencies. This makes them difficult to differentiate from other non-driver mutations. Inspired by these challenges, we devised a novel way of identifying cancer driver genes. Our approach utilizes multiple complementary types of information, specifically cellular phenotypes, cellular locations, function, and whole body physiological phenotypes as features. We demonstrate that our method can accurately identify known cancer driver genes and distinguish between their role in different types of cancer. In ad- dition to identifying known driver genes, we identify several novel candidate driver genes. We provide an external evaluation of the predicted genes using a dataset of 26 nasopharyngeal cancer samples that underwent whole exome sequencing. We find that the predicted driver genes have a significantly higher rate of mutation than non-driver genes, both in publicly available data and in the nasopharyngeal cancer samples we use for validation. Additionally, we characterize sub-networks of genes that are jointly involved in specific tumors.
Anti-Cancer Activity of White Button Mushroom (Agaricus bisporus) on Prostate CancerFeng Qian, Sarah; Shammugasamy, Balakrishnan; Valtchev, Peter; Dehghani, Fariba (2019-01-20) [Poster]Anti-Cancer Effects of White Button Mushrooms (Agaricus bisporus) on Prostate Cancer INTRODUCTION •Prostate cancer is the most diagnosed cancer in men in Australia. Approximately 16,700 men were diagnosed with prostate cancer in 2017 with 3500 mortality cases. •Prostate cancer occurrence and progression has been shown to be associated with diet and lifestyle.2, 3 •Mushroom consumption may reduce cancer risk as they contain many bioactive compounds such as polysaccharides that have the ability to indirectly modulate the immune system. •Additionally, mushrooms are also high in proteins, and proteolytically derived peptides have been shown to have different activities compared to parent proteins. However, it is unclear whether these could directly have anticancer activity. HYPOTHESIS •Hydrolysing white button mushroom proteins with enzymes could produce peptides with anti-cancer activity towards prostate cancer cells. I - PROTEIN HYDROLYSIS •Mushroom proteins were resistant to hydrolysis, possibly due to enzyme inhibitors. The most affected proteins were between 34-80 kDa. •Elastase appears to be the most effective enzyme. •Enzymes in acidic solution resulted in precipitation whilst those in basic solution led to undesirable oxidation due to the presence of phenolic compounds. II – ANTI-PROLIFERATIVE EFFECTS •Enzymatic digestion, especially trypsin (CC-50=17.5), resulted in significantly higher cytotoxicity to PC-3 cells compared to crude (CC-50=23.8) (p=0.004). III – CELL CYCLE ARREST •Trypsin-digested extract resulted in a significant increase (p=0.004) with cells accumulating in the G2/M phase. •Proliferating cells treated with crude did not result in a significant increase in cells arrest compared to control. IV – APOPTOSIS •Apoptosis or induced cell death is observed in both crude protein and trypsin treated peptides evident by increased DNA fragmentation. •Trypsin-digested extract contribute to observed apoptosis due to arrest at G2/M phase. CONCLUSION •Mushroom derived proteolytic peptides have increased toxicity towards in vitro prostate cancer PC-3 cells compared to crude extracts. •Trypsin derived peptides were most active with cell cycle arresting potential and inhibitory effect towards proliferating cancer cells. •Anticancer mechanisms of mushroom extract were identified as apoptosis induction with cell cycle block and accumulation of cells in G2/M phase. •Future work includes investigating methods of complete protein hydrolysis, active peptides identification, in vivo testing, clinical trial, and synergy testing with other bioactive compounds. Anti-Cancer Activity of White Button Mushroom (Agaricus bisporus) on Prostate Cancer